MoA messages

• • • • •

Nab-paclitaxel, developed using an innovative nanotechnology platform, leverages the natural transport properties of albumin Nab-paclitaxel is a tumor-targeted chemotherapy; it preferentially accumulates in the tumor versus healthy tissue 1,2,3

– At parity of administered dose,

Nab-paclitaxel

concentration versus conventional paclitaxel is • • 33% higher in the area of the tumour (p < 0.0001) 1 ~50% lower in healthy tissues (p <0.008) 2

Nab-paclitaxel’s MOA allows for higher administered dose 4

–

Nab-paclitaxel unique MoA translates into superior efficacy 4

– 49% higher dose vs conventional paclitaxel (260 mg/m 2 vs.175 mg/m 2 ) 4 –

Nab-paclitaxel

doubles the overall response rate (ORR) versus conventional paclitaxel in > first-line patients (26.5% versus 13.2%, p=0.006) 4

Nab-paclitaxel

extends overall survival by 2.3 months versus conventional paclitaxel in > first-line patients (13.0 versus 10.7 months, HR=0.73, p=0.024) 4

Nab-paclitaxel has a favorable tolerability profile versus conventional paclitaxel despite an average 49% greater dose 4

1) Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor based paclitaxel. Clin Cancer Res. 2006;12:1317-1324. 2) Hawkins et al. AACR. 2003. Poster 1189.

3) Scheff RJ. Breast cancer and the new taxanes: focus on nab-paclitaxel Commun Oncol 2008;5(suppl 8):7–13.

4) Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–7803.